{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    42,
    44,
    45,
    51,
    52,
    53,
    55,
    58,
    139,
    61,
    65,
    66,
    67,
    69,
    71,
    77,
    78,
    79,
    80,
    81,
    82,
    83,
    84,
    85,
    97,
    114,
    118,
    119,
    121
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 60,
        "sourceText": "treatment start",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_2",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 50,
        "sourceText": "baseline assessment",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_5",
        "definition": "Day 1 of Cycle 1",
        "anchorType": "CycleStart",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 70,
        "sourceText": "Cycle \n1, Day 1",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_3",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 20,
        "sourceText": "screening period",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_4",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 10,
        "sourceText": "informed consent",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_6",
        "definition": "procedure",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 100,
        "sourceText": "procedure",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_cycle_1",
        "type": "Cycle",
        "cycleLength": "P28D",
        "sourceText": "28-day cycle"
      },
      {
        "id": "rep_cycle_7",
        "type": "Cycle",
        "cycleLength": "P4D",
        "sourceText": "4-week \ncycle"
      },
      {
        "id": "rep_cycle_15",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until disease progression"
      },
      {
        "id": "rep_cycle_16",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until death"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "interval": "P21D",
        "minObservations": 1,
        "exitCondition": "Disease progression or unacceptable toxicity",
        "sourceText": "Administration of First and Subsequent Infusions of Atezolizumab/Placebo"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "BASELINE",
          "TREATMENT",
          "FOLLOW_UP",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "End of Study",
          "Screening",
          "Baseline Tumour Evaluation",
          "Day 1"
        ],
        "sourceText": "[{'condition': 'If subject experiences AE requiring permanent treatment discontinuation', 'path': ['TREATMENT_DISCONTINUATION', 'SAFETY_FOLLOW_UP']}, {'condition': 'If subject consents to optional research', 'path': ['RESEARCH_BIOSAMPLE_REPOSITORY']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2; SINGLE signals: 1"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Laboratory Assessments",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 1"
      },
      {
        "activityId": "Drug Administration",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2"
      },
      {
        "activityId": "Imaging",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 4; SINGLE signals: 3"
      },
      {
        "activityId": "Biopsy",
        "executionType": "Single",
        "rationale": "SINGLE signals: 6"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Informed Consent",
        "executionType": "Single",
        "rationale": "Obtained once from persons to whom the drug may be administered prior to study participation."
      },
      {
        "activityId": "Serum pharmacokinetic/anti-drug antibody samples",
        "executionType": "Single",
        "rationale": "Samples are collected at multiple time points, though the amendment notes removal of the specific Follow-Up collection."
      },
      {
        "activityId": "Adverse Event Management (Myocarditis)",
        "executionType": "Single",
        "rationale": "Triggered by signs or symptoms such as laboratory or cardiac imaging abnormalities; involves conditional management guidelines."
      },
      {
        "activityId": "Infusion-related reaction monitoring",
        "executionType": "Single",
        "rationale": "Conditional workflow based on the occurrence of reactions or cytokine-release syndrome (CRS) requiring specific grading and management."
      },
      {
        "activityId": "PD-L1 Status Assessment",
        "executionType": "Single",
        "rationale": "Assessment of PD-L1 status for patients with previously untreated TNBC to determine eligibility/stratification."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "a1. If a scheduled treatment visit cannot be completed due to a holiday, dosing may be postponed to the earliest next date; subsequent dosing should continue according to the original schedule.",
        "footnoteId": "fn_1",
        "sourceText": "a1. If a scheduled treatment visit cannot be completed due to a holiday, dosing may be postponed to "
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "a2. Assessments scheduled on the day of study treatment administration (Day 1) of each cycle should be performed prior to study treatment infusion unless otherwise noted.",
        "footnoteId": "fn_2",
        "sourceText": "a2. Assessments scheduled on the day of study treatment administration (Day 1) of each cycle should "
      },
      {
        "id": "fn_cond_3",
        "conditionType": "procedure_timepoints",
        "text": "a3. Paclitaxel will be administered at the 90 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15 of every 28-day cycle.",
        "footnoteId": "fn_3",
        "sourceText": "a3. Paclitaxel will be administered at the 90 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_after",
        "text": "b. Patients will be asked to return to the clinic within 30 days after their last study drug dose for a treatment discontinuation visit.",
        "footnoteId": "fn_4",
        "sourceText": "b. Patients will be asked to return to the clinic within 30 days after their last study drug dose fo"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "timing_before",
        "text": "c. Written informed consent is required before performing any study-specific tests or procedures.",
        "footnoteId": "fn_5",
        "sourceText": "c. Written informed consent is required before performing any study-specific tests or procedures."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "d. Demographic information includes age, gender, and self-reported race/ethnicity.",
        "footnoteId": "fn_6",
        "sourceText": "d. Demographic information includes age, gender, and self-reported race/ethnicity."
      },
      {
        "id": "fn_cond_7",
        "conditionType": "timing_before",
        "text": "e. All patients will be tested for HIV antibody, HBsAg, HBcAb, HBsAb, and hepatitis C virus antibody (HCVAb) locally, prior to the inclusion into the study.",
        "footnoteId": "fn_7",
        "sourceText": "e. All patients will be tested for HIV antibody, HBsAg, HBcAb, HBsAb, and hepatitis C virus antibody"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "timing_before",
        "text": "f. Includes all prescription or over-the-counter medications taken from 7 days prior to screening to EOS.",
        "footnoteId": "fn_8",
        "sourceText": "f. Includes all prescription or over-the-counter medications taken from 7 days prior to screening to"
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_after",
        "text": "g. Tumour assessments will be performed every 8 weeks for the first 12 months following randomisation, and every 12 weeks thereafter, until PD, death, withdrawal of consent, or study termination by the Sponsor.",
        "footnoteId": "fn_9",
        "sourceText": "g. Tumour assessments will be performed every 8 weeks for the first 12 months following randomisatio"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "h1. The EORTC QLQ-C30, QLQ-BR23, and EQ-5D-5L questionnaires and item GP5 of the FACT-G questionnaire will be completed by the patient on an electronic (ePRO) device.",
        "footnoteId": "fn_10",
        "sourceText": "h1. The EORTC QLQ-C30, QLQ-BR23, and EQ-5D-5L questionnaires and item GP5 of the FACT-G questionnair"
      },
      {
        "id": "fn_cond_11",
        "conditionType": "general",
        "text": "h2. Since item GP5 specifically assesses patients being bothered by the side-effects of treatment, this item will not be administered at baseline.",
        "footnoteId": "fn_11",
        "sourceText": "h2. Since item GP5 specifically assesses patients being bothered by the side-effects of treatment, t"
      },
      {
        "id": "fn_cond_12",
        "conditionType": "timing_before",
        "text": "i. Complete physical examination at Screening, and EOT, and symptom-driven physical examinations within 96 hours before Day 1 of each cycle.",
        "footnoteId": "fn_12",
        "structuredCondition": "timing.before(day 1 of each cycle., PT96M)",
        "timingConstraint": "PT96H",
        "sourceText": "i. Complete physical examination at Screening, and EOT, and symptom-driven physical examinations wit"
      },
      {
        "id": "fn_cond_13",
        "conditionType": "timing_before",
        "text": "j. ECOG performance status and local laboratory assessments may be obtained within 96 hours before Day 1 of each cycle.",
        "footnoteId": "fn_13",
        "structuredCondition": "timing.before(day 1 of each cycle., PT96M)",
        "timingConstraint": "PT96H",
        "sourceText": "j. ECOG performance status and local laboratory assessments may be obtained within 96 hours before D"
      },
      {
        "id": "fn_cond_14",
        "conditionType": "general",
        "text": "k. Vital signs will include measurements of respiratory rate, pulse rate, systolic and diastolic blood pressures while the patient is in a seated position.",
        "footnoteId": "fn_14",
        "sourceText": "k. Vital signs will include measurements of respiratory rate, pulse rate, systolic and diastolic blo"
      },
      {
        "id": "fn_cond_15",
        "conditionType": "timing_after",
        "text": "l. Standard 12-lead ECG, taken after resting in a supine position for at least 10 minutes.",
        "footnoteId": "fn_15",
        "timingConstraint": "PT10M",
        "sourceText": "l. Standard 12-lead ECG, taken after resting in a supine position for at least 10 minutes."
      },
      {
        "id": "fn_cond_16",
        "conditionType": "general",
        "text": "m. Haematology consists of RBC count, haemoglobin, haematocrit, WBC count with differential and platelet count. Serum chemistry includes BUN, creatinine, sodium, potassium, chloride, bicarbonate, calcium, glucose, total bilirubin, ALT, AST, alkaline phosphatase, total protein, and albumin.",
        "footnoteId": "fn_16",
        "sourceText": "m. Haematology consists of RBC count, haemoglobin, haematocrit, WBC count with differential and plat"
      },
      {
        "id": "fn_cond_17",
        "conditionType": "timing_after",
        "text": "n. Urinalysis (specific gravity, pH, glucose, protein, ketones, and blood) will be performed at screening, and thereafter only if clinically indicated.",
        "footnoteId": "fn_17",
        "sourceText": "n. Urinalysis (specific gravity, pH, glucose, protein, ketones, and blood) will be performed at scre"
      },
      {
        "id": "fn_cond_18",
        "conditionType": "timing_before",
        "text": "o. Serum pregnancy test within 7 days before Cycle 1, Day 1.",
        "footnoteId": "fn_18",
        "sourceText": "o. Serum pregnancy test within 7 days before Cycle 1, Day 1."
      },
      {
        "id": "fn_cond_19",
        "conditionType": "general",
        "text": "p. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.",
        "footnoteId": "fn_19",
        "sourceText": "p. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum preg"
      },
      {
        "id": "fn_cond_20",
        "conditionType": "timing_before",
        "text": "q. TSH, free T3 (or total T3 for sites where free T3 is not performed), and free T4 will be assessed within 96 hours before Day 1 of Cycle 1, within 96 hours before Day 1 of every second cycle thereafter, and at treatment discontinuation.",
        "footnoteId": "fn_20",
        "structuredCondition": "timing.before(day 1 of cycle 1, within 96 hours before day 1 of every second cycle thereafter, and at treatment discontinuation., PT96M)",
        "timingConstraint": "PT96H",
        "sourceText": "q. TSH, free T3 (or total T3 for sites where free T3 is not performed), and free T4 will be assessed"
      },
      {
        "id": "fn_cond_21",
        "conditionType": "general",
        "text": "r. Includes antinuclear antibody, anti-double stranded DNA, circulating anti-neutrophil cytoplasmic antibody, and perinuclear anti-neutrophil cytoplasmic antibody.",
        "footnoteId": "fn_21",
        "sourceText": "r. Includes antinuclear antibody, anti-double stranded DNA, circulating anti-neutrophil cytoplasmic "
      },
      {
        "id": "fn_cond_22",
        "conditionType": "general",
        "text": "t. Mandatory whole blood for germline DNA isolation will be collected during the Baseline visit.",
        "footnoteId": "fn_23",
        "sourceText": "t. Mandatory whole blood for germline DNA isolation will be collected during the Baseline visit."
      },
      {
        "id": "fn_cond_23",
        "conditionType": "timing_before",
        "text": "u. After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by a protocol-mandated intervention should be reported.",
        "footnoteId": "fn_24",
        "sourceText": "u. After informed consent has been obtained but prior to initiation of study drug, only SAEs caused "
      },
      {
        "id": "fn_cond_24",
        "conditionType": "timing_after",
        "text": "v. Patients should receive their first dose of study drug on the day of randomisation (no later than 3 days after randomisation).",
        "footnoteId": "fn_25",
        "sourceText": "v. Patients should receive their first dose of study drug on the day of randomisation (no later than"
      },
      {
        "id": "fn_cond_25",
        "conditionType": "timing_before",
        "text": "w. Mandatory tumour tissue biopsy collected within 3 months prior to study enrolment.",
        "footnoteId": "fn_26",
        "sourceText": "w. Mandatory tumour tissue biopsy collected within 3 months prior to study enrolment."
      },
      {
        "id": "fn_cond_26",
        "conditionType": "timing_before",
        "text": "x. Optional on-treatment tumour tissue sample collected before the Cycle 2, Day 1 dose (or within 14 days before the Cycle 2, Day 1 dose).",
        "footnoteId": "fn_27",
        "sourceText": "x. Optional on-treatment tumour tissue sample collected before the Cycle 2, Day 1 dose (or within 14"
      },
      {
        "id": "fn_cond_27",
        "conditionType": "general",
        "text": "y. Optional sample, collected (if clinically feasible) at the time (or within ±7 days) of radiographic progression (per RECIST v1.1).",
        "footnoteId": "fn_28",
        "sourceText": "y. Optional sample, collected (if clinically feasible) at the time (or within ±7 days) of radiograph"
      },
      {
        "id": "fn_cond_28",
        "conditionType": "general",
        "text": "z. All patients will be followed for survival and new anti-cancer therapy (including targeted therapy and immunotherapy) information until death, withdrawal of consent, loss to follow-up, or until study termination by the Sponsor.",
        "footnoteId": "fn_29",
        "sourceText": "z. All patients will be followed for survival and new anti-cancer therapy (including targeted therap"
      },
      {
        "id": "fn_cond_29",
        "conditionType": "general",
        "text": "a. Plasma sample for biomarker analysis Whole blood sample for germline DNA analysis",
        "footnoteId": "fn_30",
        "sourceText": "a. Plasma sample for biomarker analysis Whole blood sample for germline DNA analysis"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Progression-Free Survival (PFS)",
        "endpointType": "Primary",
        "inputs": [
          "Date of randomization",
          "Date of disease progression (RECIST v1.1)",
          "Date of death",
          "Date of last tumor assessment"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "Until first occurrence of progression or death"
        },
        "algorithm": "min(date_of_progression, date_of_death) - date_of_randomization",
        "successCriteria": "Statistically significant improvement in PFS based on stratified log-rank test (two-sided alpha 5%)",
        "sourceText": "Progression-free survival (PFS), defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause dur"
      },
      {
        "id": "ep_2",
        "name": "Secondary: Overall Survival (OS)",
        "endpointType": "Secondary",
        "inputs": [
          "Date of randomization",
          "Date of death"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "Until death"
        },
        "algorithm": "date_of_death - date_of_randomization",
        "successCriteria": "Tested hierarchically after PFS; improvement in OS in PD-L1-positive and ITT populations",
        "sourceText": "overall survival (OS) in the PD-L1-positive subpopulation; [4] OS in the ITT population"
      },
      {
        "id": "ep_3",
        "name": "Secondary: Objective Response Rate (ORR)",
        "endpointType": "Secondary",
        "inputs": [
          "Number of patients with CR",
          "Number of patients with PR",
          "Total number of patients"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "Study duration"
        },
        "algorithm": "(count(CR) + count(PR)) / total_patients",
        "successCriteria": "Proportion of patients with objective response per RECIST v1.1",
        "sourceText": "ORR by RECIST v1.1 in the PD-L1-positive, Response-evaluable subpopulation; [6] ORR by RECIST v1.1 in the ITT population."
      },
      {
        "id": "ep_4",
        "name": "Secondary: Time to deterioration in Global Health Status",
        "endpointType": "Secondary",
        "inputs": [
          "Global Health Status score",
          "Baseline score",
          "Assessment date"
        ],
        "timeWindow": {
          "reference": "baseline",
          "duration": "Study duration"
        },
        "algorithm": "date_of_first_clinically_meaningful_decrease - date_of_randomization",
        "successCriteria": "Increase in time to deterioration compared to control arm",
        "sourceText": "Time to deterioration in Global Health Status"
      },
      {
        "id": "ep_5",
        "name": "Secondary: Clinical Benefit Rate (CBR)",
        "endpointType": "Secondary",
        "inputs": [
          "CR",
          "PR",
          "SD (>= 6 months)"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "6 months minimum for SD"
        },
        "algorithm": "(count(CR) + count(PR) + count(SD >= 6 months)) / total_patients",
        "successCriteria": "Proportion of patients achieving clinical benefit",
        "sourceText": "Clinical Benefit Rate"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Overall Survival",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Death",
          "Date of Randomization"
        ],
        "derivationRule": "Date of death from any cause minus date of randomization",
        "baselineDefinition": "Date of randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization until death",
        "imputationRule": "Censored at date last known to be alive",
        "unit": "Months"
      },
      {
        "id": "dv_2",
        "name": "Time to deterioration in Global Health Status",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "EORTC QLQ-C30 Global Health Status score"
        ],
        "derivationRule": "Time from randomization to the first decrease in score of >= 10 points from baseline",
        "baselineDefinition": "Last non-missing assessment prior to first study drug administration",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization until first deterioration",
        "imputationRule": "Censored at last valid PRO assessment",
        "unit": "Months"
      },
      {
        "id": "dv_3",
        "name": "Progression-Free Survival",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Progression",
          "Date of Death",
          "Date of Randomization"
        ],
        "derivationRule": "Time from randomization to the first occurrence of disease progression or death from any cause",
        "baselineDefinition": "Date of randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization until progression or death",
        "imputationRule": "Censored at last tumor assessment",
        "unit": "Months"
      },
      {
        "id": "dv_4",
        "name": "Objective Response Rate",
        "variableType": "Categorical",
        "sourceVariables": [
          "Best Overall Response"
        ],
        "derivationRule": "Percentage of patients with a best overall response of Complete Response (CR) or Partial Response (PR)",
        "baselineDefinition": "Presence of measurable disease at baseline",
        "baselineVisit": "Screening",
        "analysisWindow": "From randomization until disease progression",
        "imputationRule": "Patients without post-baseline assessment are considered non-responders",
        "unit": "%"
      },
      {
        "id": "dv_5",
        "name": "Duration of Objective Response",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of First Response",
          "Date of Progression",
          "Date of Death"
        ],
        "derivationRule": "Time from first occurrence of CR or PR until disease progression or death",
        "baselineDefinition": "First documented response",
        "baselineVisit": "Post-baseline",
        "analysisWindow": "From first response until progression or death",
        "imputationRule": "Censored at last tumor assessment",
        "unit": "Months"
      },
      {
        "id": "dv_6",
        "name": "Clinical Benefit Rate",
        "variableType": "Categorical",
        "sourceVariables": [
          "Best Overall Response",
          "Duration of Stable Disease"
        ],
        "derivationRule": "Percentage of patients with CR, PR, or Stable Disease (SD) lasting >= 6 months",
        "baselineDefinition": "Presence of measurable or non-measurable disease at baseline",
        "baselineVisit": "Screening",
        "analysisWindow": "From randomization until 6 months post-randomization",
        "imputationRule": "Non-evaluable patients are considered non-responders",
        "unit": "%"
      },
      {
        "id": "dv_7",
        "name": "Changes from Baseline in Patient Function and Symptoms",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "EORTC QLQ-C30 score",
          "EORTC QLQ-BR23 score"
        ],
        "derivationRule": "Post-baseline score - Baseline score",
        "baselineDefinition": "Last non-missing assessment prior to first study drug administration",
        "baselineVisit": "Day 1",
        "analysisWindow": "Per assessment schedule",
        "imputationRule": "Linear mixed-effects model or MMRM",
        "unit": "Score points"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Baseline",
        "Treatment",
        "Follow Up",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Baseline",
          "trigger": "Progress to Baseline"
        },
        {
          "fromState": "Baseline",
          "toState": "Treatment",
          "trigger": "Progress to Treatment"
        },
        {
          "fromState": "Treatment",
          "toState": "Follow Up",
          "trigger": "Progress to Follow Up"
        },
        {
          "fromState": "Follow Up",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Baseline": "BASELINE",
        "Treatment": "TREATMENT",
        "Follow Up": "FOLLOW_UP",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Appendix",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 9.0,
            "unit": "g"
          }
        ],
        "sourceText": "Status Scale .............................................................................. 174 Appendix 8 Cockcroft-Gault formula ............................................................ 175 Appe"
      },
      {
        "id": "dosing_2",
        "treatmentName": "Version",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 6.0,
            "unit": "g"
          }
        ],
        "sourceText": "bilirubin ≤ 1.25× ULN Patients with known Gilbert’s disease who have serum bilirubin level ≤ 3× ULN may be enrolled. Atezolizumab—F. Hoffmann-La Roche Ltd 24/Protocol MO39196 (IMpassion131), Version 6"
      },
      {
        "id": "dosing_3",
        "treatmentName": "Type",
        "frequency": "QD",
        "route": "IV",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "g"
          }
        ],
        "sourceText": "medicinal products (IMPs) in this study. All IMPs will be supplied by the Sponsor. Atezolizumab (Investigational Drug) The atezolizumab drug product is provided in a single-use, 20cc USP/Ph. Eur. Type"
      },
      {
        "id": "dosing_4",
        "treatmentName": "Diphenhydramine",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 50.0,
            "unit": "mg"
          },
          {
            "amount": 10.0,
            "unit": "mg"
          },
          {
            "amount": 300.0,
            "unit": "mg"
          }
        ],
        "sourceText": "6 hours prior to the paclitaxel infusion Patients may be treated with dexamethasone ≤10 mg IV within 1 hour prior to the paclitaxel infusion if the patient did not take the oral dexamethasone. • Diphe"
      },
      {
        "id": "dosing_5",
        "treatmentName": "Cimetidine",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 300.0,
            "unit": "mg"
          },
          {
            "amount": 50.0,
            "unit": "mg"
          }
        ],
        "sourceText": "IV within 1 hour prior to the paclitaxel infusion if the patient did not take the oral dexamethasone. • Diphenhydramine 50 mg IV (or equivalent) 30-60 minutes prior to the paclitaxel infusion • Cimeti"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "Atezolizumab",
        "frequency": "Q2W",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Until radiographic progression or unacceptable toxicity",
        "doseModifications": [
          "Dose management guidelines updated for immune-mediated events",
          "Guidelines for infusion-related reactions and cytokine-release syndrome"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Paclitaxel",
        "frequency": "QW",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Until radiographic progression or unacceptable toxicity"
      },
      {
        "id": "dosing_llm_3",
        "treatmentName": "Placebo",
        "frequency": "Q2W",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Until radiographic progression or unacceptable toxicity"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_4",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "Tumour assessments will be performed at screening/baseline, approximately every 8 weeks (± 1 week) for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression "
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "controlled study designed to evaluate the efficacy and safety of atezolizumab (MPDL3280A, an anti-PD-L1 antibody) administered in combination with paclitaxel compared with placebo in combination with "
      },
      {
        "id": "visit_2",
        "visitName": "EOS",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "End of Study",
        "sourceText": "continue until the end of the study (EOS; defined as last patient last visit, or LPLV). In the absence of disease progression, paclitaxel and atezolizumab/placebo may be discontinued for toxicity inde"
      },
      {
        "id": "visit_3",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": false,
        "visitNumber": 4,
        "sourceText": "per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (optional sample; collected if clinically feasible from a new or progressing tumour lesion). Tumour assessments will be performed at scre"
      },
      {
        "id": "visit_5",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "1, Day 1 may be used as baseline assessments rather than repeating the tests. Tumour assessments will be performed on the specified schedule regardless of treatment delays, interruptions or discontinu"
      },
      {
        "id": "visit_llm_8",
        "visitName": "Radiographic Disease Progression",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": false,
        "visitNumber": 8,
        "epoch": "Treatment"
      },
      {
        "id": "visit_llm_9",
        "visitName": "Survival Follow-up",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 9,
        "targetWeek": 12,
        "epoch": "Follow-up"
      },
      {
        "id": "visit_6",
        "visitName": "Day 1",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 8,
        "epoch": "Treatment",
        "sourceText": "1, Day 1 may be used as baseline assessments rather than repeating the tests. Tumour assessments will be performed on the specified schedule regardless of treatment delays, interruptions or discontinu"
      },
      {
        "id": "visit_8",
        "visitName": "Day 8",
        "targetDay": 8,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "epoch": "Treatment",
        "sourceText": "administered on Day 8 of the cycle, it may be administered on Day 15 if counts have recovered to permissible levels. If paclitaxel cannot be administered on Day 15 of the cycle, the next dose of pacli"
      },
      {
        "id": "visit_9",
        "visitName": "Day 15",
        "targetDay": 15,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 10,
        "epoch": "Treatment",
        "sourceText": "recovered to permissible levels. If paclitaxel cannot be administered on Day 15 of the cycle, the next dose of paclitaxel should be administered on Day 1 of the following cycle when ANC and platelets "
      },
      {
        "id": "visit_llm_5",
        "visitName": "Cycle 2, Day 1",
        "targetDay": 29,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 5,
        "epoch": "Treatment"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Tumor Assessment (First 12 Months)",
        "targetDay": 56,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 6,
        "targetWeek": 8,
        "epoch": "Treatment"
      },
      {
        "id": "visit_7",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 13,
        "sourceText": "loss to follow-up, or study termination by the Sponsor. Information regarding PFS2, PROs and the use of subsequent anti-cancer agents for metastatic TNBC will also be collected during the survival fol"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "2:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_llm_1",
          "name": "Tumour PD-L1 status",
          "categories": [
            "IC0",
            "IC1/2/3"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Prior taxane treatment",
          "categories": [
            "Yes",
            "No"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_3",
          "name": "Presence of liver metastases",
          "categories": [
            "Yes",
            "No"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_4",
          "name": "Region",
          "categories": [
            "North America",
            "Western Europe/Australia",
            "Eastern Europe/Asia Pacific",
            "South America"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": " \nAtezolizumab—F. Hoffmann-La Roche Ltd \n19/Protocol MO39196 (IMpassion131), Version 6.0 \ntumour biopsy sample may be used. Of these additional options, the most recent sample should \nbe used.  \nStudy"
    }
  }
}